Potential biomarkers such as high tumor mutation burden (TMB), high PD-L1 protein expression on immunohistochemistry, and an immunogenic tumor microenvironment have been proposed, yet does not robustly predict treatment response9,11,12. The gene discussed is CD274; the disease is neoplasm.